Role of organic cation transporter 3 (SLC22A3) and its missense variants in the pharmacologic action of metformin

Pharmacogenetics and Genomics

Volumn 20, Issue 11, 2010, Pages 687-699

  Chen, Ligong ^a   Pawlikowski, Bradley ^b   Schlessinger, Avner ^a   More, Swati S ^a   Stryke, Doug ^a   Johns, Susan J ^a   Portman, Michael A ^a   Chen, Eugene ^a   Ferrin, Thomas E ^a   Sali, Andrej ^a   Giacomini, Kathleen M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Department of Cell and Tissue Biology ^*  (United States)

Author keywords

metformin; monoamines; muscle cells; organic cation transporters; pharmacogenomics

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; CATECHOLAMINE; CIMETIDINE; HISTAMINE; HYBRID PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; METFORMIN; MONOAMINE; ORGANIC CATION TRANSPORTER 3; SHORT HAIRPIN RNA;

ARTICLE; CELL MEMBRANE; CELLULAR DISTRIBUTION; DRUG EFFECT; DRUG INHIBITION; DRUG TARGETING; DRUG UPTAKE; GENETIC VARIABILITY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIVER; MISSENSE MUTATION; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SKELETAL MUSCLE;

EID: 78049298630     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32833fe789     Document Type: Article

References (44)

1. Koepsell H, Lips K, Volk C. Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharmcol Res 2007; 24:1227-1251.
2. Jonker JW, Schinkel AH. Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3). J Pharmcol Exp Ther 2004; 308:2-9.
3. Zwart R, Verhaagh S, Buitelaar M, Popp-Snijders C, Barlow DP. Impaired activity of the extraneuronal monoamine transporter system known as uptake-2 in Orct3/Slc22a3-deficient mice. Mol Cell Biol 2001; 21:4188-4196.
4. Grundemann D, Schechinger B, Rappold GA, Schomig E. Molecular identification of the corticosterone-sensitive extraneuronal catecholamine transporter. Nat Neurosci 1998; 1:349-351.
5. Ogasawara M, Yamauchi K, Satoh Y, Yarnaji R, Inui K, Jonker JW, et al. Recent advances in molecular pharmacology of the histamine systems: organic cation transporters as a histamine transporter and histamine metabolism. J Pharmacol Sci 2006; 101:24-30.
6. Kimura N, Masuda S, Katsura T, Inui K. Transport of guanidine compounds by human organic cation transporters, hOCT1 and hOCT2. Biochem Pharmcol 2009; 77:1429-1436.
7. Vialou V, Amphoux A, Zwart R, Giros B, Gautron S. Organic cation transporter 3 (Slc22a3) is implicated in salt-intake regulation. J Neurosci 2004; 24:2846-2851.
8. Baganz NL, Horton RE, Calderon AS, Owens WA, Munn JL, Watts LT, et al. Organic cation transporter 3: keeping the brake on extracellular serotonin in serotonin-transporter-deficient mice. Proc Natl Acad Sci \USA 2008; 105:18976-18981.
9. Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L, Dhanasekaran SM, et al. Integrative molecular concept modeling of prostate cancer progression. Nat Genet 2007; 39:41-51.
10. Trégouët DA, König IR, Erdmann J, Munteanu A, Braund PS, Hall AS, et al.; Wellcome Trust Case Control Consortium; Cardiogenics Consortium. Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease. Nat Genet 2009; 41:283-285.
11. Yeager M, Orr N, Hayes RB, Jacobs KB, Kraft P, Wacholder S, et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet 2007; 39:645-649.
12. Ashiya M, Smith RE. Non-insulin therapies for type 2 diabetes. Nat Rev Drug Discov 2007; 6:777-778.
13. Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro RA, et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 2007; 117:1422-1431.
14. Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response. Pharmacogenet Genomics 2010; 20:38-44.
15. Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus. Pharmacogenomics J 2009; 9:242-247.
16. Tsuda M, Terada T, Ueba M, Sato T, Masuda S, Katsura T, Inui K. Involvement of human multidrug and toxin extrusion 1 in the drug interaction between cimetidine and metformin in renal epithelial cells. J Pharmacol Exp Ther 2009; 329:185-191.
17. Tsuda M, Terada T, Mizuno T, Katsura T, Shimakura J, Inui K. Targeted disruption of the multidrug and toxin extrusion 1 (mate1) gene in mice reduces renal secretion of metformin. Mol Pharmacol 2009; 75:1280-1286.
18. Nies AT, Koepsell H, Winter S, Burk O, Klein K, Kerb R, et al. Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology 2009; 50:1227-1240.
19. Lazar A, Walitza S, Jetter A, Gerlach M, Warnke A, Herpertz-Dahlmann B, et al. Novel mutations of the extraneuronal monoamine transporter gene in children and adolescents with obsessive-compulsive disorder. Int J Neuropsychopharmacol 2008; 11:35-48.
20. Lazar A, Grundemann D, Berkels R, Taubert D, Zimmermann T, Schomig E. Genetic variability of the extraneuronal monoamine transporter EMT (SLC22A3). J Hum Genet 2003; 48:226-230.
21. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108:1167-1174.
22. Zang MW, Zuccollo A, Hou XY, Nagata D, Walsh K, Herscovitz H, et al. AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulin-resistant human HepG2 cells. J Biol Chem 2004; 279:47898-47905.
23. Urban TJ, Yang C, Lagpacan LL, Brown C, Castro RA, Taylor TR, et al. Functional effects of protein sequence polymorphisms in the organic cation/ergothioneine transporter OCTN1 (SLC22A4). Pharmacogenet Genomics 2007; 17:773-782.
24. Pieper U, Eswar N, Braberg H, Madhusudhan MS, Davis FP, Stuart AC, et al. MODBASE, a database of annotated comparative protein structure models and associated resources. Nucleic Acids Res 2009; 37:347-354.
25. Sali A, Blundell TL. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 1993; 234:779-815.
26. Huang Y, Lemieux MJ, Song J, Auer M, Wang DN. Structure and mechanism of the glycerol-3-phosphate transporter from Escherichia coli. Science 2003; 301:616-620.
27. Bennett-Lovsey RM, Herbert AD, Sternberg MJ, Kelley LA. Exploring the extremes of sequence/structure space with ensemble fold recognition in the program Phyre. Proteins 2008; 70:611-625.
28. Shen MY, Sali A. Statistical potential for assessment and prediction of protein structures. Protein Sci 2006; 15:2507-2524.
29. Abramson J, Smirnova I, Kasho V, Verner G, Kaback HR, Iwata S. Structure and mechanism of the lactose permease of Escherichia coli. Science 2003; 301:610-615.
30. Popp C, Gorboulev V, Muller TD, Gorbunov D, Shatskaya N, Koepsell H. Amino acids critical for substrate affinity of rat organic cation transporter 1 line the substrate binding region in a model derived from the tertiary structure of lactose permease. Mol Pharmacol 2005; 67:1600-1611.
31. Edgar RC. MUSCLE: a multiple sequence alignment method with reduced time and space complexity. BMC Bioinformatics 2004; 5:113.
32. Bleasby K, Castle JC, Roberts CJ, Cheng C, Bailey WJ, Sina JF, et al. Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: a resource for investigations into drug disposition. Xenobiotica 2006; 36:963-988.
33. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med 2002; 137:25-33.
34. Musi N, Hirshman MF, Nygren J, Svanfeldt M, Bavenholm P, Rooyackers O, et al. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 2002; 51:2074-2081.
35. Grundemann D, Liebich G, Kiefer N, Koster S, Schomig E. Selective substrates for non-neuronal monoamine transporters. Mol Pharmacol 1999; 56:1-10.
36. Chen Y, Li S, Brown C, Cheatham S, Castro RA, Leabman MK, et al. Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin. Pharmacogenet Genomics 2009; 19:497-504.
37. Abbud W, Habinowski S, Zhang JZ, Kendrew J, Elkairi FS, Kemp BE, et al. Stimulation of AMP-activated protein kinase (AMPK) is associated with enhancement of Glut1-mediated glucose transport. Arch Biochem Biophys 2000; 380:347-352.
38. Somogyi A, Stockley C, Keal J, Rolan P, Bochner F. Reduction of metformin renal tubular secretion by cimetidine in man. Br J Clin Pharmacol 1987; 23:545-551.
39. Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, and Fleming GA. Lactic acidosis in patients with diabetes treated with metformin. New Eng J Med 1998; 338:265-266.
40. Vialou V, Balasse L, Callebert J, Launay JM, Giros B, Gautron S. Altered aminergic neurotransmission in the brain of organic cation transporter 3-deficient mice. J Neurochem 2008; 106:1471-1482.
41. Mooney JJ, Samson JA, Hennen J, Pappalardo K, McHale N, Alpert J, et al. Enhanced norepinephrine output during long-term desipramine treatment: a possible role for the extraneuronal monoamine transporter (SLC22A3). J Psychiatr Res 2008; 42:605-611.
42. Schneider E, Machavoine F, Pleau JM, Bertron AF, Thurmond RL, Ohtsu H, et al. Organic cation transporter 3 modulates murine basophil functions by controlling intracellular histamine levels. J Exp Med 2005; 202:387-393.
43. Becker MS, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study. Diabetes 2009; 58:745-749.
44. Wang ZJ, Yin OQ, Tomlinson B, Chow MS. OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine. Pharmacogenet Genomics 2008; 18:637-645.